No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 24
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
The latest delayed quote for TransCode Therapeutics, Inc. (RNAZ) stock was $1.73 as of Oct 6, 2026, 2:42 PM EDT, down 1.99% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -83.3% · 3-year avg -94.7%/yr · 5-year avg -93.4%/yr
TransCode Therapeutics, Inc. is a biopharmaceutical firm dedicated to pioneering and marketing therapeutic agents and diagnostic tools specifically aimed at combating and detecting metastatic disease.
Biotechnology · Boston, MA
Next Earnings Date
Nov 18, 2026
43 days away
EPS Estimate
N/A
Revenue Est.
N/A
Last Quarter Results
EPS
$-1286.15
vs Estimate
$-89.88
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1RNAZ | $1.83M | $1.73 | -1.99% | -83.28% | -93.39% | N/A | N/A |
| 2TNON | $1.83M | $3.69 | -0.24% | -91.30% | N/A | N/A | vs RNAZ |
| 3PFSA | $1.87M | $1.70 | -2.83% | -99.93% | N/A | N/A | vs RNAZ |
| 4XAIR | $1.88M | $2.61 | -8.06% | -94.08% | -76.73% | N/A | vs RNAZ |
| 5TCRT | $1.76M | $0.72 | -9.57% | -68.76% | -69.13% | -50.22% | vs RNAZ |
| 6AMIX | $1.92M | $3.53 | -0.28% | -85.08% | N/A | N/A | vs RNAZ |
forward FY estimate
N/A
$0.00
vs Estimate
N/A
Consensus Rating
No analyst recommendations available
Average Price Target
N/A
Low
N/A
Current
$1.73
High
N/A
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Dec 2026 | $-184800.00 | $-184800.00 | $-184800.00 | 1 |
| Quarter ending Jun 2027 | $-266112.00 | $-266112.00 | $-266112.00 | 1 |
| Quarter ending Sep 2027 | $-243936.00 | $-243936.00 | $-243936.00 | 1 |
| Quarter ending Dec 2027 | $-280896.00 | $-280896.00 | $-280896.00 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-8.96 | $-8.96 | $-8.96 | 1 |
| FY 2027 | $-6.72 | $-6.72 | $-6.72 | 1 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Dec 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Jun 2027 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Sep 2027 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Dec 2027 | $0.00 | $0.00 | $0.00 | 0 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $500000.00 | $500000.00 | $500000.00 | 1 |
| FY 2027 | $9.70M | $9.70M | $9.70M | 1 |
